Axa S.A. Ngm Biopharmaceuticals Inc Transaction History

Axa S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $25,620 - $47,565	10,500 New	10,500 $27,000
Q4 2022 Feb 14, 2023	SELL	$3.41 - $12.93 $996,003 - $3.78 Million	-292,083 Reduced 72.0%	113,600 $570,000
Q3 2022 Feb 14, 2023	BUY	$12.59 - $17.67 $40,791 - $57,250	3,240 Added 0.81%	405,683 $5.31 Million
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $40,791 - $57,250	3,240 Added 0.81%	405,683 $5.31 Million
Q2 2022 Feb 14, 2023	SELL	$10.58 - $17.5 $82,788 - $136,937	-7,825 Reduced 1.91%	402,443 $5.16 Million
Q2 2022 Aug 15, 2022	SELL	$10.58 - $17.5 $82,788 - $136,937	-7,825 Reduced 1.91%	402,443 $5.16 Million
Q1 2022 Feb 14, 2023	BUY	$13.81 - $18.6 $63,318 - $85,281	4,585 Added 1.13%	410,268 $6.26 Million
Q1 2022 May 13, 2022	BUY	$13.81 - $18.6 $55 - $74	4 Added 0.0%	410,268 $6.26 Million
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $84,522 - $107,831	4,897 Added 1.21%	410,264 $7.27 Million
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $2.28 Million - $2.96 Million	112,926 Added 38.61%	405,367 $8.52 Million
Q2 2021 Aug 13, 2021	BUY	$15.06 - $30.03 $4.4 Million - $8.78 Million	292,441 New	292,441 $5.77 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.